NERV vs TECH · P/E 2.2, $12.4M cap vs P/E 65, rev $1.22B
Minerva Neurosciences Inc (NERV) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Minerva Neurosciences Inc (NERV) is a biotechnology company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported NERV revenue for 2024-12-31 was $0. Net income was $1.4M. NERV currently screens at market cap $12.4M and trailing P/E 2.2.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
NERV currently screens at market cap $12.4M and trailing P/E 2.2. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the NERV and TECH stock pages for the full models.
Not investment advice.